GenMark Diagnostics: Scott Mendel, Hany Massarany, Kevin O’Boyle, James Fox
GenMark Diagnostics has appointed Scott Mendel, its chief operating officer, as interim president and CEO, effective immediately. Hany Massarany has stepped down as president and CEO and as a member of the company’s board of directors, also effective immediately. GenMark said it has commenced a search to identify a permanent CEO.
The firm appointed Kevin O’Boyle as chairman of the board. James Fox, GenMark’s prior chairman, will remain on the board as a non-executive director.
PreludeDx: Edwin Hendrick
PreludeDx has appointed Edwin Hendrick as the company's chief commercial officer. He has more than 30 years of related commercial experience and was most recently at Biocept. Before that, he was at Decipher Biosciences, formerly called GenomeDx, and at Plus Diagnostics. Laguna Hills, California-based PreludeDx's main product is the DCISionRT risk assessment test for patients with ductal carcinoma in situ.
Sophia Genetics: Philippe Menu
Sophia Genetics has named Philippe Menu as chief medical officer. Menu joined the Swiss bioinformatics company from McKinsey, where he was co-leader of the McKinsey Cancer Center. A physician with a PhD in molecular biology, Menu primarily advised pharmaceutical and biotech companies in the development of new therapies and diagnostics in oncology and rare diseases. At Sophia, he will lead the firm's medical strategy.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.